India’s market for diabetes and weight-loss medications is poised for a major shift as Danish pharmaceutical company Novo Nordisk faces the expiration of its semaglutide patent this week. This development is expected to open the door for a surge of lower-cost generic versions produced by local Indian drugmakers, while also raising concerns about inconsistent regulation in an already crowded market.
Analysts and doctors predict that more than 40 Indian companies could launch over 50 generic brands in the coming weeks. This influx is likely to increase access to semaglutide in India’s highly price-sensitive market, making the drug more affordable for patients. At the same time, the rapid expansion of options may lead to potential misuse, confusion among prescribers, and challenges in maintaining consistent standards of quality and safety.
Read Also – UK Health Authorities Warn of Rising Meningitis Cases in Kent
“With high demand, falling prices and multiple brands, you may see direct pharmacy purchases, distributor-level leakages, or cosmetic or lifestyle use especially in urban markets,” said Salil Kallianpur, an independent analyst.
“This could lead to misuse, poor titration and unmanaged side effects and eventually regulatory tightening.”
India’s drug regulator did not respond to requests for comment. Semaglutide is a prescription-only medication, but enforcement in India has historically been inconsistent, with doctors and pharmacists serving as the main gatekeepers.
The arrival of generic versions will also pose a challenge to Novo Nordisk and U.S. rival Eli Lilly, which introduced its blockbuster diabetes and obesity treatments in India last year while aiming to strengthen its market presence. Lilly’s Mounjaro quickly became India’s top-selling drug by value within months of its launch, according to data from research firm Pharmarack.
India, the world’s most populous country, has the second-highest number of adults with diabetes after China and is projected to have more than 440 million overweight or obese people by 2050, according to The Lancet and the International Diabetes Federation.
EYES ON PRICING
Indian generic drugmakers, recognized worldwide for producing affordable medicines, are expected to launch semaglutide generics at steep discounts of 50% to 60% or more.
Analysts predict that the monthly cost for the lowest dose could drop from roughly 11,000 rupees to between 3,000 and 5,000 rupees as the first generics hit the market, and eventually decline further to around 1,500 to 2,500 rupees. This dramatic price reduction could make the drug accessible to a much wider population, moving beyond a niche urban elite and reaching price-sensitive patients across the country.
“I will consult my doctor to check if I can move to using a generic version, as that appears to be lighter on the pocket,” said 32-year-old Vishal, a tech worker from Hyderabad, who is considering a switch from Wegovy.
Many patients in India’s largely out-of-pocket healthcare market have started asking about more affordable alternatives, with some generic versions expected to launch as early as Saturday, just one day after Novo Nordisk’s patent expires.
“The price range being quoted is broadly 2,500 to 3,500 rupees, which is quite low,” said bariatric surgeon Venugopal Pareek. Six of his patients are waiting for generic versions to switch from Novo or Lilly drugs.
Lower prices are expected to expand the patient pool.
“Onboarding of patients from lower economic strata may happen on branded generics,” said Sheetal Sapale, commercial vice president at Pharmarack, noting that company profits would depend on pricing discipline.
DOCTORS’ CHOICE
Even as prices drop, analysts say that success in the market will depend not only on cost but also on the confidence of doctors. India’s pharmaceutical sector is largely driven by physician prescriptions, so uptake of generics will rely heavily on how familiar and comfortable doctors are with specific brands.
Analysts warn that the initial flood of new products may overwhelm prescribers, with inconsistent experiences and aggressive marketing creating potential confusion. Many generic drugmakers are using brand names that include “sema,” which could further complicate identification and selection.
Over time, experts expect doctors’ trust to consolidate around a smaller group of manufacturers that can reliably provide consistent supply, high-quality delivery devices, and predictable patient outcomes, ultimately shaping the long-term winners in the market.
“Weaker players with poor quality and no differentiation will likely exit within two to three years,” Kallianpur said.
